Amalgamated Bank Supernus Pharmaceuticals, Inc. Transaction History
Amalgamated Bank
- $11.7 Billion
- Q2 2024
A detailed history of Amalgamated Bank transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 16,376 shares of SUPN stock, worth $559,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,376
Previous 16,817
2.62%
Holding current value
$559,240
Previous $574,000
23.69%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding SUPN
# of Institutions
258Shares Held
59.3MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$355 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$210 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$180 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$97.9 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$91.5 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.83B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...